EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Germline Mutational Profile of Triple-Negative Breast Cancer in Portugal: A Multicenter Retrospective Cohort Study

Marta Serafim Gonçalves, Ricardo Roque, Isália Miguel, Inês Baptista Freitas, Olga Caramelo, Patrícia Gago, Susana Almeida, Teresa Fraga, Tatiana Cunha Pereira, Sofia Broco, Teresa Carvalho, Gabriela Sousa

DNA · 12.11.2026 · 6 (4) · 57

DOI: 10.3390/dna6040057 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift DNA, online erschienen am 12.11.2026. Verfasst von Marta Serafim Gonçalves und 11 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Portuguese reseArch gRoup breasT caNcEr (PARTNER)–Sociedade Portuguesa de Oncologia.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Triple-negative breast cancer (TNBC) carries a poor prognosis; while PARP inhibitors (PARPi) are approved for BRCA-mutated disease, other homologous recombination deficiency (HRD) pathways may be actionable targets. This study characterizes germline mutations in Portuguese TNBC and explores exploratory associations with clinicopathologic features and outcomes.

Methods

A multicentric retrospective cohort of women diagnosed with TNBC (2022–2024) that harbored a pathogenic variant (PV), likely pathogenic variant (LPV), or variant of uncertain significance (VUS) across six Portuguese institutions. Clinicopathologic variables were compared between groups. Overall (OS) and progression-free survival (PFS) were estimated in patients eligible for curative-intent therapy with PV/LPV, using Kaplan–Meier and log-rank methods.

Results

Among 109 patients, 38.5% carried a PV and 11.0% an LPV. BRCA1/2 predominated among PV carriers (59.5%), followed by PALB2 (9.5%), RAD51C (7.1%), and RAD51D (4.8%). Additionally, 53.2% harbored a VUS, mainly ATM (22.4%), CHEK2/BRCA2 (8.6% each), and NF1 (6.9%). Mean age was 49.7 ± 12.1 years; 49.5% had advanced-stage disease (>cT2/N+); 61.5% received neoadjuvant immunotherapy; 1.8% received adjuvant PARPi. For efficacy analysis, BRCA (n = 26) and non-BRCA (n = 25) carriers were well balanced. Pathologic complete response occurred in 60.9% of non-BRCA versus 82.6% of BRCA carriers (p = 0.190). BRCA carriers had numerically higher PFS (p = 0.09): 92.3% versus 69.7% at 24 months. OS was comparable (p = 0.16); median OS not reached.

Conclusions

This study characterizes the germline landscape of Portuguese TNBC, revealing diverse HRD-pathway mutations beyond BRCA. In this small exploratory analysis, BRCA status was not associated with a statistically significant difference in PFS, pathologic response, or OS.

Förderung

  • Portuguese reseArch gRoup breasT caNcEr (PARTNER)–Sociedade Portuguesa de Oncologia

Zitieren

APA

Gonçalves, M. S., Roque, R., Miguel, I., Freitas, I. B., Caramelo, O., Gago, P., Almeida, S., Fraga, T., Pereira, T. C., Broco, S., Carvalho, T., & Sousa, G. (2026). Germline Mutational Profile of Triple-Negative Breast Cancer in Portugal: A Multicenter Retrospective Cohort Study. DNA, 6(4), 57. https://doi.org/10.3390/dna6040057

Vancouver

Gonçalves MS, Roque R, Miguel I, Freitas IB, Caramelo O, Gago P, et al. Germline Mutational Profile of Triple-Negative Breast Cancer in Portugal: A Multicenter Retrospective Cohort Study. DNA. 2026;6(4):57. doi:10.3390/dna6040057

BibTeX
@article{Gonalves2026,
  author = {Gonçalves, Marta Serafim and Roque, Ricardo and Miguel, Isália and Freitas, Inês Baptista and Caramelo, Olga and Gago, Patrícia and Almeida, Susana and Fraga, Teresa and Pereira, Tatiana Cunha and Broco, Sofia and Carvalho, Teresa and Sousa, Gabriela},
  title = {Germline Mutational Profile of Triple-Negative Breast Cancer in Portugal: A Multicenter Retrospective Cohort Study},
  journal = {DNA},
  year = {2026},
  volume = {6},
  number = {4},
  pages = {57},
  doi = {10.3390/dna6040057}
}
Kostenlos starten →